Drug news
Newron Pharma licenses US and EU rights to safinamide for Parkinsons Disease to Zambon SPA
Newron Pharma has agreed with Zambon SPA to licence safinamide, an add-on therapy to dopamine agonists and levodopa in patients with Parkinson's Disease, in the EU and USA and has granted an option exercisable by 17 April 2012 to permit Zambon SPA to acquire ROW rights to the drug except the territories of Japan and Asia where the drug is to be marketed by Meiji Seika. Two Phase III trials for safinamide being the MOTION and SETTLE studies, are ongoing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins